Instrument Inactif

Communiqués Theratechnologies Inc.

Actions

TH

CA88338H7040

Produits pharmaceutiques

Communiqués

05/12	"A Change Is A Change" – The Supreme Court Rejects A Narrow Interpretation Of "Material Change"	AQ
25/09/25	Theratechnologies Announces Completion of Acquisition by Future Pak	AQ
16/09/25	Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak	AQ
12/09/25	Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak	AQ
05/09/25	Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy	AQ
02/09/25	Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak	AQ
18/08/25	Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak	AQ
09/07/25	Theratechnologies : Q2 Interim Consolidated May 31, 2025vFINAL	PU
09/07/25	Theratechnologies : MDA Q2 2025 VFINAL	PU
09/07/25	Theratechnologies : FS Q2 2025 V6 FRE	PU
09/07/25	Theratechnologies : MDA Q2 2025 V4 FRE	PU
09/07/25	Theratechnologies: Fiscal Q2 Earnings Snapshot	AQ
09/07/25	Theratechnologies Reports Financial Results for the Second Quarter 2025	AQ
03/07/25	Theratechnologies to Announce Second Quarter 2025 Financial Results	AQ
03/07/25	Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak	AQ
29/05/25	Theratechnologies Reports on its Annual Meeting of Shareholders	AQ
03/05/25	Theratechnologies : Thera Circular 2025 vFINAL	PU
02/05/25	Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV	AQ
16/04/25	Theratechnologies Provides Update on Sale Process	AQ
14/04/25	Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value	AQ
12/04/25	Soleus Capital Issues Letter to The Board of Theratechnologies	BU
11/04/25	Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company	AQ
10/04/25	Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements	AQ
09/04/25	Theratechnologies Receives FDA Approval of Prior Approval Supplement for EGRIFTA SV sBLA	AQ
09/04/25	Theratechnologies : Quarterly Management's Discussion & Analysis Q1	PU